Its over for them...RBC states the Pfizer-Flynn Decision as the reason for their downgrade this morning to UNDERPERFORM PRICE TARGET OF $1.00
WOW. Bondholders are likely now to stop the payment to Cinven in light of the CMA's decision, triggering a default and the capital structure to crumble. Karma to this drug gouger and kudos to the shorts who said five months ago that it would be the international part of the business that would cause them to file. Rather ironic, since they bought AMCO in the first place to reduce their drug pricing risk in the U.S. LMFA !